Factors Influencing Route of Administration for Epoetin Treatment Among Hemodialysis Patients in the United States

American Journal of Kidney Diseases

Volumn 48, Issue 1, 2006, Pages 77-87

  Thamer, Mae ^a,b   Zhang, Yi ^a,b   Kaufman, James ^a,b   Stefanik, Kevin ^a,b   Cotter, Dennis J ^a,b  

^a Medical Technology and Practice Patterns Institute   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anemia management; clinical guidelines; cost; cost savings; erythropoietin; pharmacotherapy; practice pattern variation; route of administration

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DECISION MAKING; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PHYSICIAN; SOCIAL ASPECT; STUDENT T TEST; UNITED STATES;

ADULT; AGED; COHORT STUDIES; COST SAVINGS; DECISION MAKING; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MEDICARE; MIDDLE AGED; OWNERSHIP; PHYSICIAN INCENTIVE PLANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RENAL DIALYSIS; UNITED STATES;

EID: 33745200769     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.03.040     Document Type: Article

References (49)

1. Levin A. Preaching and practice: Evidence-based medicine and the accountability of nephrologists within the healthcare system. The implications of the findings of the cost-saving potential of subcutaneous versus intravenous epoetin therapy. Am J Kidney Dis 40 (2002) 662-663
2. Wish J.B. Can evidence drive the development of a sound national EPO reimbursement policy?. Am J Kidney Dis 41 (2003) 254-258
3. Kaufman J.S. Subcutaneous erythropoietin therapy. Efficacy and economic implications. Am J Kidney Dis 32 suppl 4 (1998) S147-S151
4. US General Accounting Office. Dialysis Facilities. Problems Remain in Ensuring Compliance with Medicare Quality Standards (2003), US Government Accountability Office, Washington, DC GAO-04-63
5. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14 suppl 5 (1999) S1-S50
6. Barrett B.J., Fenton S.S., Ferguson B., et al., Canadian Society of Nephrology. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. J Am Soc Nephrol 10 suppl 13 (1999) S292-S296
7. Centers for Medicare & Medicaid Services. 2004 Annual Report, End Stage Renal Disease Clinical Performance Measures Project (2004), Department of Health and Human Services, Centers for Medicare & Medicaid Services, Baltimore, MD
8. National Center for Cost Containment, Department of Veterans Affairs. FY97 Veterans Affairs Dialysis Case Mix Study 1998 (1998), National Center for Cost Containment, Milwaukee, WI
9. Kaufman J.S., Reda D.J., Fye C.L., et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339 (1998) 578-583
10. Besarab A., Reyes C.M., and Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (2002) 439-446
11. Klinkmann H., Schmidt R., Wieczorek L., and Scigalla P. Adverse events of subcutaneous recombinant human erythropoietin therapy. Contrib Nephrol 100 (1992) 127-138
12. Allegra V., Martimbianco L., Mengozzi G., and Vasile A. Erythropoietin and cardiovascular risk. Blood Purif 13 (1995) 301-313
13. Navarro J.F., Teruel J.L., Marcen R., and Ortuno J. Improvements of erythropoietin-induced hypertension in hemodialysis patients changing the administration route. Scand J Urol Nephrol 29 (1995) 11-14
14. Kang D.H., Yoon J.I., and Han D.S. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol Dial Transplant 13 (1998) 1877-2883
15. Weiss L. Flexible dosing schemes for recombinant human erythropoietin-Lessons from our daily practice. Nephrol Dial Transplant 16 suppl 7 (2001) S15-S19
16. Mason N.A., St Peter W.L., Bailie G.R., and Johnson C.A. Clinical and practical perspectives on the use of intravenous vs subcutaneous epoetin alfa in hemodialysis patients. Dial Transplant 30 (2001) 522-546
17. Frankenfield D.L., and Johnson C.A. Current management of anemia in adult hemodialysis patients with end-stage renal disease. Am J Health Syst Pharm 59 (2002) 429-435
18. Reddan D.N., Frankenfield D.L., Klassen P.S., et al. Regional variability in anemia management and haemoglobin in the US. Nephrol Dial Transplant 18 (2003) 147-152
19. US Renal Data System. 2001 Researcher's Guide to the CPM Standard Analysis Files ADR Edition (2001), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
20. Frankenfield D.L., Prowant B.F., Flanigan M.J., et al., ESRD Core Indicators Workgroup. Trends in clinical indicators of care for adult peritoneal dialysis patients in the United States from 1995 to 1997. Kidney Int 55 (1999) 1998-2010
21. Frankenfield D.L., Rocco M.V., Frederick P.R., et al. Racial/ethnic analysis of selected intermediate outcomes for hemodialysis patients. Results from the 1997 ESRD Core Indicators Project. Am J Kidney Dis 34 (1999) 721-730
22. DHHS, Centers for Medicare & Medicaid Services. 2003 Annual Report. ESRD Clinical Performance Measures Project. Am J Kidney Dis 44 suppl 2 (2004) S1-S92
23. Frankenfield D.L., Roman S.H., Rocco M.V., Bedinger M.R., and McClellan W.M. Disparity in outcomes for adult Native American hemodialysis patients? Findings from the ESRD Clinical Performance Measures Project, 1996 to 1999. Kidney Int 65 (2004) 1426-1434
24. van Manen J.G., Korevaar J.C., Dekker F.W., et al. How to adjust for comorbidity in survival studies in ESRD patients. A comparison of different indices. Am J Kidney Dis 40 (2002) 82-89
25. Kidney Epidemiology and Cost Center: Bundled Drugs and Laboratory Tests. March 11, 2005; p 3. Available at: http://www.google.com/search?q=cache:qWiNqQxu5o8J:www.cms.hhs.gov/faca/esrd/tab_D.pdf+%22Bundled+drugs+and+laboratory+tests%22&hl=en. Accessed October 28, 2005
26. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Evaluation, classification, and stratification. Am J Kidney Dis 39 suppl 1 (2002) S1-S246
27. Liang K.Y., and Zeger S.L. Regression analysis for correlated data. Annu Rev Public Health 14 (1993) 43-68
28. Localio A.R., Berlin J.A., Ten Have T.R., and Kimmel S.E. Adjustments for center in multicenter studies. An overview. Ann Intern Med 135 (2001) 112-123
29. Frenken L., van Lier H.J., Gerlag P.G., et al. Assessment of pain after subcutaneous injection of erythropoietin in patient receiving hemodialysis. BMJ 303 (1991) 288 abstr
30. Paganini E.P., Eschbach J.W., Lazarus J.M., et al. Intravenous versus subcutaneous dosing of epoetin alpha in hemodialysis patients. Am J Kidney Dis 26 (1995) 331-340
31. Schlesinger M., Cleary P.D., and Blumenthal D. The ownership of health facilities and clinical decision-making. The case of the ESRD industry. Med Care 27 (1989) 244-258
32. Helgerson S.D., McClellan W.M., Frederick P.R., et al. Improvement in adequacy of delivered dialysis for adult in-center hemodialysis patients in the United States, 1993 to 1995. Am J Kidney Dis 29 (1997) 851-861
33. Hirth R.A., Tedeschi P.J., and Wheeler J.R. Extent and sources of geographic variation in Medicare end-stage renal disease expenditures. Am J Kidney Dis 38 (2001) 824-831
34. De Lissovoy G., Powe N.R., Griffiths R.I., et al. The relationship of provider organizational status and erythropoietin dosing in end-stage renal disease patients. Med Care 321 (1994) 130-140
35. US Renal Data System. USRDS 2004 Annual Data Report (2004), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
36. DePalma J.R. External quality review will not improve American ESRD healthcare. Dial Transplant 29 (2000) 694-686
37. Medicare Payment Advisory Commission. Report to the Congress. Quality of dialysis care and providers' costs, in Variation and Innovation in Medicare, chap 6 (2003), MedPAC, Washington, DC 91-98
38. Pisoni R.L., Gillespie B.W., Dickinson D.M., et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS). Design, data elements, and methodology. Am J Kidney Dis 44 suppl 2 (2004) S7-S15
39. Locatelli F., Pisoni R.L., Combe C., et al. Anaemia in haemodialysis patients of five European countries. Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (2004) 121-132
40. Securities and Exchange Commission: Fresenius Medical Care Holdings. Form 10-Q. Available at: http://www.sec.gov/Archives/edgar/data/42872/0000950135-99-005389.txt. Accessed 2000.
41. Medicare Payment Advisory Commission. Report to Congress. Medicare Payment Policy, chap 8 (2001), MedPAC, Washington, DC 123-138
42. US Renal Data System. USRDS 2002 Annual Data Report (2002), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
43. Goozner M. The Making and Selling of a Star Drug. Chicago Tribune (1999) May 24
44. Held P.J., Garcia J.R., Pauly M.V., and Cahn M.A. Price of dialysis, unit staffing, and length of dialysis treatments. Am J Kidney Dis 15 (1990) 441-450
45. Roberts T.L., Obrador G.T., St Peter W.L., Pereira B.J.G., and Collins A.J. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 66 (2004) 2429-2436
46. Cabana M.D., Rand C.S., Powe N.R., et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282 (1999) 1458-1465
47. Besarab A., Reyes C.M., and Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (2002) 439-446
48. Besarab A. Optimizing anaemia management with subcutaneous administration of epoetin. Nephrol Dial Transplant 20 suppl 6 (2005) Svi10-Svi15
49. Locatelli F., and Del Vecchio L. Pure red cell aplasia secondary to treatment with erythropoietin. J Nephrol 16 (2003) 461-466